Tesamorelin Research Overview: GHRH Analog in Preclinical Studies

Published: March 2026

Tesamorelin (GHRH Analog): Research Overview

Overview

Tesamorelin is a synthetic peptide analog of endogenous Growth Hormone-Releasing Hormone (GHRH), the hypothalamic peptide that drives pulsatile growth hormone (GH) secretion from the anterior pituitary. Structurally, tesamorelin corresponds to the full 44-amino-acid sequence of human GHRH(1-44)-NH₂, with the critical modification of a trans-3-hexenoic acid moiety conjugated at the N-terminus. This structural addition confers markedly enhanced stability against dipeptidyl peptidase-IV (DPP-IV)–mediated cleavage, extending the effective half-life of the molecule without altering its receptor pharmacology. The compound was developed under the investigational designation TH9507 and is also referenced in the literature as trans-3-hexenoic acid-GHRH(1-44)-NH₂.

Tesamorelin is the only GHRH analog to receive regulatory approval by the U.S. Food and Drug Administration, where it is approved under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy — a clinical condition arising from long-term antiretroviral therapy. This approval was grounded in two pivotal Phase III randomized controlled trials demonstrating significant, measurable reductions in visceral adipose tissue (VAT) relative to placebo. The FDA approval context provides important framing for the compound’s mechanism of action and has positioned tesamorelin as one of the most thoroughly characterized GHRH analogs in the peer-reviewed literature.

Beyond its regulatory context, tesamorelin has attracted substantial interest as a research tool for probing the GH/IGF-1 axis in conditions ranging from metabolic liver disease to age-related cognitive decline. The availability of a clinically characterized, pharmacologically stable GHRH analog has enabled controlled investigations into the role of GH pulsatility in body composition, hepatic metabolism, and neuroendocrine function in ways that were not previously feasible with native GHRH, which degrades within seconds of systemic administration.

Molecular Profile

Mechanism of Action

Tesamorelin exerts its biological activity through high-affinity binding to the growth hormone-releasing hormone receptor (GHRHR), a class B G protein-coupled receptor expressed on somatotroph cells of the anterior pituitary gland. Binding of tesamorelin to GHRHR activates adenylyl cyclase via G_αs coupling, generating cyclic AMP (cAMP) and activating protein kinase A (PKA). This intracellular cascade mobilizes intracellular calcium stores and opens voltage-gated calcium channels, triggering exocytosis of pre-formed GH secretory granules. Importantly, the trans-3-hexenoic acid modification at the N-terminus preserves full agonist activity at GHRHR while blocking proteolytic degradation at the Tyr¹-Ala² bond — the primary DPP-IV cleavage site — thereby sustaining receptor engagement for a pharmacologically relevant duration following subcutaneous administration.

The downstream consequence of GHRHR activation is stimulation of pulsatile GH secretion that closely approximates the endogenous ultradian rhythm. Unlike exogenous recombinant GH, which delivers a pharmacological bolus and suppresses endogenous secretion via negative feedback, GHRH analogs preserve the physiological pulse architecture of GH release by working through the pituitary’s intrinsic secretory machinery. Released GH then acts on target tissues — primarily the liver — to stimulate transcription and secretion of insulin-like growth factor 1 (IGF-1). IGF-1, in turn, mediates the majority of GH’s anabolic and metabolic effects, including modulation of lipolysis in visceral adipose depots, stimulation of protein synthesis in skeletal muscle, and regulation of hepatic lipid metabolism. Circulating IGF-1 also participates in negative feedback at both the hypothalamus and pituitary to maintain physiological GH tone, a regulatory loop that remains functionally intact under GHRH analog stimulation.

At the tissue level, GH-driven lipolysis in visceral adipose tissue (VAT) proceeds through hormone-sensitive lipase activation and reduced lipoprotein lipase activity, promoting net efflux of free fatty acids from intra-abdominal fat depots. Concurrently, IGF-1 signaling through the IGF-1 receptor (IGF-1R) activates the PI3K/AKT/mTOR pathway in hepatocytes and myocytes, influencing fatty acid oxidation, de novo lipogenesis, and insulin sensitivity. The specificity of tesamorelin’s effects on visceral versus subcutaneous fat compartments is an active area of research interest, with studies examining the differential expression of GHRHR, IGF-1R, and GH receptor subtypes across adipose depots as a potential mechanistic explanation.

Key Areas of Investigation

HIV-Associated Lipodystrophy and Visceral Adiposity

The largest body of published research on tesamorelin has examined its effects on visceral fat accumulation in the context of HIV-associated lipodystrophy. Falutz et al. conducted a pivotal 12-month randomized, placebo-controlled trial in 404 HIV-infected adults with central fat accumulation, reporting that tesamorelin (2 mg subcutaneous daily) was associated with a statistically significant reduction in visceral adipose tissue of approximately 10.9% at six months (PMID: 20101189). An earlier Phase III trial (PMID: 18057338) in 412 participants found a 15.2% decrease in VAT in the tesamorelin arm versus a 5.0% increase in the placebo arm over 26 weeks, with concomitant reductions in triglyceride levels, establishing the foundation for regulatory review.

Hepatic Fat and Non-Alcoholic Fatty Liver Disease

Research has investigated whether tesamorelin’s effects on VAT extend to intrahepatic lipid accumulation. Stanley et al. published a randomized clinical trial in JAMA (2014, PMID: 25038357) in 50 HIV-infected adults, finding that tesamorelin was associated with reductions in both visceral fat and hepatic fat fraction as measured by proton magnetic resonance spectroscopy. A subsequent dedicated randomized double-blind multicenter trial published in Lancet HIV (2020, PMID: 31611038) enrolled 61 HIV-infected adults with NAFLD and reported that tesamorelin was associated with a 37% relative reduction in hepatic fat fraction compared to placebo over 12 months, with an observed attenuation of fibrosis progression in the treated group.

GH/IGF-1 Axis and Body Composition

Studies have characterized changes in serum IGF-1, IGF-binding protein 3 (IGFBP-3), and GH pulse parameters following tesamorelin administration, establishing that the compound restores pulsatile GH secretion toward younger physiological norms. A study published in the Journal of Clinical Endocrinology & Metabolism (PMID: 31237318) examined tesamorelin’s effects on intramuscular fat and total muscle cross-sectional area in HIV-infected adults, finding a statistically significant reduction in muscle fat infiltration and increase in muscle area — offering a framework for understanding how GHRH-axis stimulation may influence skeletal muscle composition beyond adipose tissue compartments.

Neurocognitive Function and the GHRH Axis

The relationship between the somatotropic axis and cognitive function has been an emerging area of investigation, based on the well-documented age-related decline in hypothalamic GHRH tone. Baker et al. conducted a randomized, double-blind, placebo-controlled trial published in Archives of Neurology (2012, PMID: 22869065) in 152 adults with mild cognitive impairment and healthy older adults, reporting that GHRH analog administration was associated with favorable effects on executive function domain scores compared to placebo. A companion neuroimaging study (PMID: 23689947) using magnetic resonance spectroscopy found that 20 weeks of GHRH administration was associated with increased GABA levels in multiple brain regions and decreased myo-inositol in the posterior cingulate cortex — neurochemical signatures proposed as potential mechanistic substrates of the observed cognitive effects.

Metabolic Profile and Lipid Parameters

Independent of the adipose tissue findings, studies have examined whether tesamorelin-associated reductions in VAT translate into measurable changes in cardiometabolic risk markers. Analysis of metabolic outcomes from Phase III trial data found that reduction in visceral adiposity following tesamorelin administration was associated with changes in triglyceride levels, HDL cholesterol, and inflammatory markers including high-sensitivity C-reactive protein (hsCRP) (PMID: 22495074). Published data have also indicated no clinically significant worsening of fasting glucose or insulin sensitivity indices in study populations — a relevant consideration given that supra-physiological GH levels are associated with insulin resistance.

Key Published References

1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370. PMID: 18057338
2. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311–322. PMID: 20101189
3. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380–389. PMID: 25038357
4. Mallon PW, Yan D, Cooper DA, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2020;7(1):e37–e48. PMID: 31611038
5. Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol. 2012;69(11):1420–1429. PMID: 22869065
6. Friedman SD, Baker LD, Borson S, et al. Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol. 2013;70(7):883–890. PMID: 23689947
7. Sinnott B, Ramos A, Nazeeri A, et al. The growth hormone releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV. J Clin Endocrinol Metab. 2019;104(11):5285–5293. PMID: 31237318

Product Availability

Tesamorelin (10 mg) is available for qualified research applications through White Market Peptides: Tesamorelin 10 mg — Research Grade.